Cancer
Research conducted by a team at Toho University in Tokyo, Japan, has shed light on the relationship between estrogen receptor-b gene cytosine-adenine (ESR2-CA) repeat polymorphism and colon cancer. The study, published in the International Journal of Molecular Sciences, investigated the impact of ESR2-CA repeats on colon cancer in postmenopausal women.
Cancer
Glioblastoma (GBM) is the most aggressive and malignant primary brain tumor in adults, with a median overall survival (OS) after diagnosis of approximately 2 years and a 5-year OS that is poor. Despite the use of multimodality treatment involving surgical resection, radiation therapy, chemotherapy, and tumor-treating fields, a need for
Cancer
Researchers have found that cancer survivors are at a higher risk of developing type 2 diabetes, often as a result of obesity and insulin resistance. While it is unclear whether diabetes susceptibility is due to shared risk factors for cancer and insulin resistance or directly related to cancer and its
Cancer
The cancer immunotherapy market size is estimated to be USD 110,125.4 million in 2022, with a significant growth potential due to the surge in oncology incidence around the world and the rise in R&D efforts for novel oncology treatments. Top companies such as Novartis AG, Lilly,
Cancer
Researchers in Guangdong, People's Republic of China, have conducted a study to investigate the relationship between DNA methylation and tumor mutation burden (TMB) in colorectal cancer (CRC) patients. The study, led by Hao Huang, aimed to identify clinical benefit populations and evaluate the effect of immune checkpoint inhibitor
Cancer
Researchers at the Cedars-Sinai Medical Center have made a breakthrough in developing a more effective treatment for glioblastomas, a highly aggressive form of brain cancer. The study, published in the journal Scientific Reports, details the development of an activated T cell therapy that targets cancer stem cells in glioblastomas. This
Cancer
Researchers at the University of California, San Francisco (UCSF) are leading a Phase 1 clinical trial to investigate the safety and efficacy of combining niraparib and irinotecan in treating cancers with mutations in DNA repair genes. The trial, which is currently not open for recruiting, aims to enroll 24 participants
Cancer
Research from the University of Texas MD Anderson Cancer Center has highlighted the importance of early intervention to prevent or minimize radiation therapy-induced side effects in patients with non-small cell lung cancer. The study emphasizes the need for monitoring and predicting cardiopulmonary toxicities before treatment begins. The researchers suggest that
Cancer
Young adult cancer survivors are vulnerable to subsequent human papillomavirus (HPV)-related malignancies, particularly due to high-risk sexual behavior. Research highlights the importance of HPV vaccination in protecting against infection among this population. A study conducted at the University of Alabama Birmingham found that cancer survivors engage in sexual behaviors
Cancer
A new study published in the journal Cancers has made a significant breakthrough in personalized medicine, identifying mutations in * * FBXW7* * and * * SMAD4* * as predictors of clinical outcome in metastatic colorectal cancer. The research, conducted by a team of scientists from the University of Barcelona, used next-generation sequencing (NGS) to analyze
Cancer
Researchers at the Indian Institute of Science Education and Research have made a significant discovery in the field of biotechnology, specifically in cancer gene therapy. By understanding the sulfation pattern of glycosaminoglycans (GAGs), such as heparan sulfate (HS) and chondroitin sulfate (CS), scientists have developed a potential drug- or gene-delivery
Cancer
Researchers from Central South University have published a new study on the identification and validation of a prognostic model based on ferroptosis-associated genes in head and neck squamous cancer. The study used ferroptosis marker genes to identify three stable molecular subtypes (C1, C2, C3) with distinct prognostic, mutational, and immune
